reason report
fundament guid still intact despit challeng
bottom line share trade experienc
unusu weak quarter compani miss sale vs
mid-singl digit organ growth estim factor
uniqu reflect broader sector weak
major miss come weak high
resolut mass spec categori account
sale beyond weak india sale combin weak
china appli market food/ environmental/industri made
wors sale forc realign effort maintain
guidanc still remain confid long-term outlook
believ issu specif share recov
see impact op op mp op
lst name univers
liquid chromatographi compani core heart
liquid chromatographi lc compani strong posit
qa/qc regul drug power cd chromatographi data
system call empow glue togeth drive strong sale
among custom mass spec smaller part
high end high resolut omic mass spec known qtof
quadrupol time-of flight account sale
instrument gener bought biopharma discovery/development
group lead academ lab becom increasingli
import biomolecul recent highlight given high-
end non-routin natur instrument asp
sale gener lumpi exactli experienc
quarter remain confid sale return back
next quarter messag convey keep guidanc
india sale much help alreadi tough quarter india
account sale well sell mostli allianc
hplc indian gener pharma manufactur recal
first time rough quarter india current quarter
made wors earlier india good servic tax gst impact
almost alway india sale return back lc wide use
among indian gener pharma expect sale return
year
sale forc realign effort align sale forc
line applic food proteom chemic etc rather
generalist sale person pull specialist
need align also led sale disrupt larg
food environment chemic market
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu mm ep present ex-amort one-tim charg
pleas refer page import disclosur price chart analyst certif
guid remain intact share repurchas drive benefit
next year reiter guid also initi
share repurchas program drove ep estim
rate water share outperform rate price target
view water posit believ growth biopharma end-market like
continu strengthen wat alreadi establish presenc biopharma qa/qc lab
biomolecul continu becom increasingli larger part poveral drug volum
world-wide continu garner premium price lc liquid chromatographi
market given best-in-class uplc system mass spec attach rate highest
industri china continu deliv double-digit growth driven demand pharma food
environmental/industri test lab underli strength recur revenu
base almost wat revenu remain sticki biopharma qa/qc lab gener
amen chang
limit exposur academ fund world-wide less exposur
direct nih fund us believ short-term concern around stock misplac
given minim exposur academ govern revenu biopharma qa/
qc lab account revenu come lc busi
believ wat core biopharma qa/qc lab continu see robust growth back
biotherapeut emerg market includ china india remain strong china
believ experienc surg instrument sale driven chines fda attempt improv
overal profil chines biopharma industri result instrument upgrad lab
china constitut sale like grow higher china continu post
double-digit growth near team deriv revenu intern
asia suggest number continu grow come year solidifi
presenc intern compani
maintain op rate pt move reflect premium
ev/ebitda lst multipl share current trade ev/ebitda
consensu estim turn tool averag believ
abl reach multipl potenti higher given premium natur
mass spec product line-up continu growth biopharma increasingli
biotherapeut enter qa/qc lab drive increas util sale even higher
uniqu differenti uplc platform continu gain market share back
high attach rate deriv price target appli premium averag
ev/ebitda multipl compris life scienc peer group
primari risk price target includ
biopharma declin pose greatest risk wat revenu slowdown
biopharmaceut fund number factor includ chang regul fda
approv process directli impact biopharma biotech compani
polit risk pose threat biopharma drug sale result sharp reduct
spend current level fifty-six percent revenu deriv biopharma
reduct expens biopharma like impact compani
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim signific academ exposur revenu
ww nih exposur less revenu nevertheless slowdown academ
spend could headwind plan margin expans restrict global
budget could result shift focu strategi growth could increas oper
risk declin government spend could risk downsid forecast growth
well
emerg market pose signific risk wat revenu sudden macroeconom
impact china lead declin fund could impact advers china
repres compani revenu current grow mid-teen china
chang regul lead restrict oper china foreign compani like
impact compani sale significantli
high attach rate integr part busi model disrupt could
impact revenu impact abil maintain high attach rate lc
system due chang technolog competit chang market competitor offer
superior product compar uplc increas competitor lc space could impact
water market share disrupt market model consum
fda regul remain paramount affect adopt rate clinic
diagnost tool clinic diagnost remain major growth area futur
chang regul restrict use mass spectromet clinic diagnost
laboratori could also sever affect compani restrict could affect growth adopt
rate certain tool regul would also increas cost complianc test purpos
would result declin estim
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report leerink partner estim
